

Gibson Dunn Deal Wins IFLR Asia-Pacific Awards 2022 Private Equity Deal of the Year

[Accolades](#) | [March 18, 2022](#)

International Financial Law Journal

International Financial Law Review named China Biologic Products' take-private, a transaction on which Gibson Dunn advised, as its Private Equity Deal of the Year at the IFLR Asia-Pacific Awards 2022. The awards were announced on March 17, 2022. Gibson, Dunn & Crutcher's Beijing office is dedicated to servicing the needs of our clients establishing operations and doing business in China and those of our Chinese clients in their international transactions. The Beijing office works closely with lawyers in our Hong Kong office, enabling us to provide Hong Kong law capability where relevant.

Related Capabilities

[Private Equity](#)